Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 182

1.

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.

Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, Yuthavisuthi P, Chirayus S, Ngo-Giang-Huong N, Voramongkol N, Pattarakulwanich S, Lallemant M; PHPT-5 Team.

AIDS. 2010 Sep 10;24(14):2193-200. doi: 10.1097/QAD.0b013e32833ce57d.

PMID:
20625263
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Reduced lopinavir exposure during pregnancy.

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.

AIDS. 2006 Oct 3;20(15):1931-9.

PMID:
16988514
[PubMed - indexed for MEDLINE]
3.

Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.

Chadwick EG, Pinto J, Yogev R, Alvero CG, Hughes MD, Palumbo P, Robbins B, Hazra R, Serchuck L, Heckman BE, Purdue L, Browning R, Luzuriaga K, Rodman J, Capparelli E; International Maternal Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team.

Pediatr Infect Dis J. 2009 Mar;28(3):215-9. doi: 10.1097/INF.0b013e31818cc053.

PMID:
19209098
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy.

Chadwick EG, Yogev R, Alvero CG, Hughes MD, Hazra R, Pinto JA, Robbins BL, Heckman BE, Palumbo PE, Capparelli EV; International Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team.

AIDS. 2011 Mar 13;25(5):643-9. doi: 10.1097/QAD.0b013e32834403f6.

PMID:
21297419
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.

Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.

Antivir Ther. 2007;12(6):963-9.

PMID:
17926651
[PubMed - indexed for MEDLINE]
6.

Lopinavir exposure with an increased dose during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Holland DT, Smith E, Gaddipati S, Read JS; PACTG 1026s Study Team.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):485-91. doi: 10.1097/QAI.0b013e318186edd0.

PMID:
18989231
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.

Cressey TR, Van Dyke R, Jourdain G, Puthanakit T, Roongpisuthipong A, Achalapong J, Yuthavisuthi P, Prommas S, Chotivanich N, Maupin R, Smith E, Shapiro DE, Mirochnick M; IMPAACT P1032 Team.

Antimicrob Agents Chemother. 2009 May;53(5):2189-91. doi: 10.1128/AAC.01091-08. Epub 2009 Feb 23.

PMID:
19237646
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L.

AIDS. 2009 Aug 24;23(13):1679-88. doi: 10.1097/QAD.0b013e32832d7350.

PMID:
19487905
[PubMed - indexed for MEDLINE]
9.

Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.

Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, Eley T, Child M, Bertz R, Hu W, Wirtz V, McGrath D.

HIV Med. 2011 Oct;12(9):570-9. doi: 10.1111/j.1468-1293.2011.00927.x. Epub 2011 May 16.

PMID:
21569187
[PubMed - indexed for MEDLINE]
10.

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

van der Lee M, Verweel G, de Groot R, Burger D.

Antivir Ther. 2006;11(4):439-45.

PMID:
16856617
[PubMed - indexed for MEDLINE]
11.

Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.

Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, Smith ME, Alvero C, Fenton T, Heckman B, Pelton SI, Aldrovandi G, Borkowsky W, Rodman J, Havens PL; PACTG 1038 Team.

Antimicrob Agents Chemother. 2008 Sep;52(9):3276-83. doi: 10.1128/AAC.00224-08. Epub 2008 Jul 14.

PMID:
18625762
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

A randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir/ritonavir dosage in pregnancy.

Bonafe SM, Costa DA, Vaz MJ, Senise JF, Pott-Junior H, Machado RH, Castelo A.

AIDS Patient Care STDS. 2013 Nov;27(11):589-95. doi: 10.1089/apc.2013.0159. Epub 2013 Oct 19.

PMID:
24138537
[PubMed - indexed for MEDLINE]
13.

Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.

Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH, Chen J, Palumbo P, Serchuck L, Smith E, Hughes M; P1030 team.

AIDS. 2008 Jan 11;22(2):249-55.

PMID:
18097227
[PubMed - indexed for MEDLINE]
14.

Reduced indinavir exposure during pregnancy.

Cressey TR, Best BM, Achalapong J, Stek A, Wang J, Chotivanich N, Yuthavisuthi P, Suriyachai P, Prommas S, Shapiro DE, Watts DH, Smith E, Capparelli E, Kreitchmann R, Mirochnick M; IMPAACT P1026s team.

Br J Clin Pharmacol. 2013 Sep;76(3):475-83. doi: 10.1111/bcp.12078.

PMID:
23305215
[PubMed - indexed for MEDLINE]
15.

Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.

Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A.

Antimicrob Agents Chemother. 2004 Nov;48(11):4256-62.

PMID:
15504850
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):201-5.

PMID:
17414932
[PubMed - indexed for MEDLINE]
17.

Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.

Tubiana R, Mandelbrot L, Le Chenadec J, Delmas S, Rouzioux C, Hirt D, Treluyer JM, Ekoukou D, Bui E, Chaix ML, Blanche S, Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group.

Clin Infect Dis. 2013 Sep;57(6):891-902. doi: 10.1093/cid/cit390. Epub 2013 Jun 12.

PMID:
23766338
[PubMed - indexed for MEDLINE]
18.

Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.

Puthanakit T, van der Lugt J, Bunupuradah T, Ananworanich J, Gorowara M, Phasomsap C, Jupimai T, Boonrak P, Pancharoen C, Burger D, Ruxrungtham K.

J Antimicrob Chemother. 2009 Nov;64(5):1080-6. doi: 10.1093/jac/dkp322. Epub 2009 Sep 2.

PMID:
19729375
[PubMed - indexed for MEDLINE]
Free Article
19.

Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy.

Ramautarsing RA, van der Lugt J, Gorowara M, Kerr SJ, Burger D, Ruxrungtham K, Phanuphak P, Chaithongwongwatthana S, Avihingsanon A, Phanuphak N.

AIDS. 2011 Jun 19;25(10):1299-303. doi: 10.1097/QAD.0b013e328347f7e9.

PMID:
21516029
[PubMed - indexed for MEDLINE]
20.

Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.

van Heeswijk RP, Bourbeau M, Seguin I, Giguere P, Garber GE, Cameron DW.

Br J Clin Pharmacol. 2005 Apr;59(4):398-404.

PMID:
15801934
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk